Clinical trial CABL001J12301
A Phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Cancers | |
---|---|
Organ | LMC |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Novartis |
EudraCT Identifier | 2021-000678-27 |
Inclusion criteria | 1.Male or female patients ? 18 years of age.2.Patients with CML-CP within 3 months of diagnosis*3.Diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL1 in a review of a minimum 20 m |
Last update |